Our new review explores how the definition of high-risk Ph+ ALL is shifting across tx eras.
Risk is dynamic, shaped by the interplay of biology, response, and treatment context. We examine key determinants, their evolving relevance, and risk-adapted strategies in the current era.
A dream come true. Absolutely thrilled to have matched at @MDAndersonNews for heme/onc fellowship. Grateful for my incredible support system, the mentors who shaped my path, and my training at @BCM_InternalMed.
#FellowMatch
Thrilled to congratulate everyone on Match Day, especially the newly matched @MDAndersonNews Hematology & Medical Oncology Fellowship Class of 2029! #EndCancer
• HR Ph- ALL who achieved early NGS MRD neg→favorable long-term survival
• HR Ph- ALL and suboptimal MRD dynamics→poor outcomes and benefitted from alloSCT in first remission
• Early NGS MRD dynamics can refine risk stratification and may guide consolidative tx decisions
Check out our most recent publication in @BloodCancerJnl evaluating the prognostic impact of early NGS-based MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL.
https://t.co/uR43j02ClQ
@NicholasShortMD@DrHKantarjian#Leusm#ALLsm
Survival of adult #ALL is significantly better 👍
‼️ Ph ➖ ALL: Adding antibodies & immunotherapy is crucial, in frontline & salvage
‼️ Ph➕ ALL: Chemotherapy-free approach improves survival & spares transplant
#leusm@DrHKantarjian@SocietyofHemOnc@OncoAlert
Expert recommendations on using MRD in #ALL now out in @BloodAdvances. ClonoSEQ (NGS MRD) is superior to other MRD methods and should guide decisions about CAR T-cells or SCT
@MDAndersonNews#Leukemia
https://t.co/eQLDCAbR4H
#leusm
Our @TXMedCenter before WWII and today (my photo from a Southwest Airlines flight). Today our Texas Medical Center in Houston is the world’s largest, and also the first biomedicine city of >100,000 employees, >60 institutions, including several medical schools
CONGRESS #ASH24 | PRESENTATION
@WNMacaron, @MDAndersonNews and @bcmhouston discussed achievement of MRD negativity and positive long-term outcomes in B-ALL. In pts with PH- B-ALL , 2-yr RFS was higher in pts who were MRD neg after cycle 1, vs those who were pos after cycle 1. Poorer outcomes occurred in pts with HR B-ALL and slow MRD response. Follow our live feed for more updates: https://t.co/fDCz3La5Dx
#ALL #ALLsm
Although immune checkpoint inhibitors demonstrate modest activity in cardiac soft tissue sarcomas, durable benefit was observed in a subset of patients w/ nonangiosarcoma, albeit w/ higher toxicity. https://t.co/Clz7NnoTWw
#JACCCardioOnc#CardioOnc#Immunotherapy@AminNassarMD
Adding gilteritinib to azacitidine and venetoclax shows improved outcomes in patients with FLT3-mutated acute myeloid leukemia, according to a study led by MD Anderson researchers. https://t.co/6zAT5lu8u2 @NicholasShortMD@DrHKantarjian@Daver_Leukemia@TapKadia#AML#EndCancer
Our paper on aza + ven +gilteritinib for FLT3mut #AML now online at @JCO_ASCO
In frontline FLT3mut AML, CR 90% (vs. 30-50% with aza+ven) and 18mo OS 72% (vs. 2yr OS 20-40% with aza+ven)
Could be delivered safely with appropriate dose modifications.
https://t.co/JZmsMproiW